COMPANY

OCULOGENEX

Keywords: gene therapy macular degeneration

Location: Dallas, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.09M (SBIR Phase II 1R44EY038510-01, new, notice Aug 4, 2026). NIH RePORTER 1R44EY038510-01 (Aug 4, 2026)
Evidence (1 event)
- Aug 4, 2026 · NIH RePORTER 1R44EY038510-01
  Organization: OCULOGENEX; City/State: Dallas, TX; Project number: 1R44EY038510-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 1092536; Administering IC: National Eye Institute; Project title: Developing a gene therapy-based solution for early intervention in age related macular degeneration (AMD) to prevent disease progression; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Aug 4, 2026 Grant Government grant — SBIR: $1.09M (annual award, as published), announced Aug 4, 2026. Agency: NIH/NEI. Source: government award database. source ↗

Last 2 years.

Aug 4, 2026 Government grant — SBIR: $1.09M (annual award, as published), announced Aug 4, 2026. Agency: NIH/NEI. Source: government award database. source ↗